Danuglipron: A Literature Course on What the Studies Report

Danuglipron, also identified in the literature by its development code PF-06882961, is an orally administered small-molecule agonist of the glucagon-like peptide-1 receptor (GLP-1R). It has been examined in randomised trials in adults with type 2 diabetes and in adults with obesity, in meta-analyses pooling those trials, and in a small number of preclinical and analytical papers. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or research participation. Nothing here is a protocol, a recommendation, or a description of what any individual should do.

The course is organised into six modules. Each module closes with a short statement of the limits of the evidence, because the published record on danuglipron is dominated by early- and mid-phase studies rather than long-term outcome trials.

Module 1: What Danuglipron Is and How It Has Been Studied

Definition and class

Danuglipron is classified in the literature as an oral, small-molecule GLP-1 receptor agonist. That classification matters for anyone who encounters the compound alongside injectable GLP-1 medicines: a 2025 patent review of "next-in-class" danuglipron- and lotiglipron-like GLP-1R agonists described this group as non-peptide chemical entities designed for oral administration, distinguishing them from peptide-based receptor agonists (PMID 40873282). Danuglipron is therefore not a peptide, and the phrase "danuglipron peptide" does not match how the molecule is described in the published chemistry literature (PMID 40873282).

Origin and forms studied

The compound entered the peer-reviewed record with a randomised, placebo-controlled, multiple-ascending-dose phase 1 trial in adults with type 2 diabetes, published in 2021, which evaluated orally dosed danuglipron and reported effects on glycaemic measures and body weight relative to placebo (PMID 34127852). Subsequent phase 2 work used oral tablets given on twice-daily schedules, and one 12-week randomised, placebo-controlled phase 2 study was designed specifically to compare different dose-escalation schemes in type 2 diabetes (PMID 37311722).

The shape of the evidence base

• Phase 1: a multiple-ascending-dose, placebo-controlled trial in type 2 diabetes (PMID 34127852).
• Phase 2 in type 2 diabetes: a 12-week dose-escalation-comparison study (PMID 37311722) and a randomised clinical trial of glycaemic control published in 2023 (PMID 37213102).
• Phase 2b in obesity: a randomised, placebo-controlled, dose-ranging study in adults with obesity published in 2025 (PMID 40539310).
• Pooled analyses: systematic reviews and meta-analyses of randomised trials of danuglipron, in some cases alongside orforglipron (PMID 37852529, PMID 37954886, PMID 41450584).
• Preclinical and analytical: a mouse cardiac remodelling study (PMID 40070049), an in silico docking study (PMID 40838124), a metabolite identification study (PMID 40865303) and a clinical pharmacology study in renal impairment (PMID 37840155).

Limits of the evidence in Module 1

The clinical record consists of phase 1 and phase 2 studies in adults with type 2 diabetes or obesity. No phase 3 trial and no long-term cardiovascular or renal outcome trial of danuglipron appears in the verified literature summarised here, and the compound has not been characterised in children, in pregnancy, or in populations without diabetes or obesity.

Module 2: Mechanism as Described in the Literature

GLP-1 receptor agonism

Across the clinical papers, danuglipron is described as an agonist at the GLP-1 receptor, and the phase 1 trial framed its pharmacodynamic assessment around glucose-lowering and body-weight endpoints consistent with GLP-1 receptor activation (PMID 34127852). The 12-week phase 2 study likewise reported pharmacodynamic measures alongside tolerability, treating receptor agonism as the presumed driver of both the glycaemic signal and the gastrointestinal adverse events (PMID 37311722).

Small-molecule binding and chemotype

The 2025 patent review placed danuglipron within a defined chemical series of orally bioavailable GLP-1R agonists and catalogued the patent landscape for related structures filed between 2020 and 2024, describing the medicinal-chemistry rationale for non-peptide receptor activation (PMID 40873282).

Exploratory off-target and organ-level mechanisms

Two mechanistic papers looked beyond glycaemic pharmacology. A 2025 molecular docking study modelled danuglipron computationally and reported potential crossovers between GLP-1R and components of the endocannabinoid system, which the authors framed as a hypothesis generated in silico rather than a demonstrated pharmacological effect (PMID 40838124). Separately, researchers reported that danuglipron ameliorated pressure overload-induced cardiac remodelling in an animal model, and attributed the observed effect to signalling through the AMPK pathway (PMID 40070049).

Limits of the evidence in Module 2

Mechanistic claims in this area rest on different evidence tiers. The receptor-agonist description is supported by clinical pharmacodynamics, whereas the endocannabinoid crossover is a docking prediction with no confirmatory human data in the verified literature (PMID 40838124), and the AMPK-linked cardiac finding comes from an animal pressure-overload model rather than from people (PMID 40070049). None of these papers established that a given mechanism explains any clinical endpoint.

Module 3: Reported Outcomes by Study

Type 2 diabetes trials

In the phase 1 multiple-ascending-dose trial, researchers randomised adults with type 2 diabetes to danuglipron or placebo and reported reductions in glycaemic measures and in body weight in the active groups relative to placebo, alongside a predominance of gastrointestinal adverse events (PMID 34127852). The 2023 randomised clinical trial of glycaemic control in type 2 diabetes reported greater reductions in HbA1c with danuglipron than with placebo across the dose levels tested, with body weight also lower than placebo (PMID 37213102). The 12-week phase 2 escalation study focused on tolerability, safety and pharmacodynamics, and reported that different dose-escalation schemes produced different tolerability profiles while glycaemic pharmacodynamic effects were observed across schemes (PMID 37311722).

Obesity trial

The randomised, placebo-controlled, dose-ranging phase 2b study in adults with obesity reported greater body-weight reduction with danuglipron than with placebo, together with frequent gastrointestinal adverse events and substantial treatment discontinuation in the active arms (PMID 40539310).

Pooled analyses

A 2023 systematic review and meta-analysis of randomised controlled trials of the oral small-molecule agonists orforglipron and danuglipron reported reductions in HbA1c and body weight versus placebo, accompanied by an increased risk of gastrointestinal adverse events (PMID 37852529). A second 2023 meta-analysis restricted to danuglipron in type 2 diabetes also reported improved glycaemic control relative to placebo with a safety signal concentrated in gastrointestinal events (PMID 37954886). A 2025 systematic review and meta-analysis of danuglipron and orforglipron in type 2 diabetes and obesity reached similar directional conclusions about efficacy and tolerability (PMID 41450584).

Limits of the evidence in Module 3

All clinical outcomes above are short- to medium-term surrogate endpoints — HbA1c, body weight, tolerability — not clinical events such as myocardial infarction, stroke or mortality. The obesity and diabetes trials were dose-ranging or dose-escalation studies rather than confirmatory efficacy trials, and pooled analyses inherit the limitations of the small number of trials available (PMID 41450584). None of these publications establishes a benefit that would generalise beyond the populations and durations studied.

Module 4: Danuglipron Side Effects: What Studies Report

Gastrointestinal events dominated the safety picture

Across the clinical programme, the most frequently reported adverse events were gastrointestinal. The phase 1 trial reported nausea, vomiting and related gastrointestinal events as the most common treatment-emergent events in participants receiving danuglipron (PMID 34127852). The 2023 randomised trial in type 2 diabetes similarly reported nausea, vomiting and diarrhoea more often with danuglipron than with placebo (PMID 37213102).

Escalation schedule and tolerability

Because gastrointestinal intolerance shaped the programme, one phase 2 study was built specifically to compare dose-escalation schemes over 12 weeks, and researchers reported that the pattern and burden of gastrointestinal adverse events differed between the schemes tested (PMID 37311722).

Discontinuation in the obesity trial

The phase 2b dose-ranging study in adults with obesity reported high rates of nausea, vomiting and diarrhoea in the danuglipron arms and a substantial proportion of participants discontinuing study treatment, with adverse events as a leading reason (PMID 40539310).

Pooled safety estimates

Meta-analyses quantified the same pattern at the group level: the 2023 pooled analysis of orforglipron and danuglipron trials reported an increased relative risk of gastrointestinal adverse events versus placebo (PMID 37852529), and the danuglipron-specific meta-analysis reported a comparable safety signal alongside glycaemic efficacy (PMID 37954886). The 2025 systematic review of danuglipron and orforglipron in type 2 diabetes and obesity again reported gastrointestinal adverse events as the principal tolerability concern (PMID 41450584).

Limits of the evidence in Module 4

Trial safety data describe what happened in selected, monitored participants over weeks to months, not what happens with prolonged use or in people excluded by trial criteria. Rare events cannot be detected at these sample sizes, and the pooled analyses combined trials with differing designs and dose schedules (PMID 37852529). No verified publication summarised here reports post-marketing surveillance data, because danuglipron has not been marketed.

Module 5: Pharmacokinetics Where Data Exist

Clinical pharmacology in renal impairment

A dedicated clinical pharmacology study examined the effect of renal impairment on the pharmacokinetics of a single oral dose of danuglipron in participants with type 2 diabetes, comparing exposure across categories of kidney function (PMID 37840155). Studies of this type are standard in drug development to determine whether exposure differs enough between renal-function groups to matter for dosing decisions, and the publication reported the resulting exposure comparisons (PMID 37840155).

Metabolism and metabolite profiling

A 2026 analytical study used UHPLC-QToF-MS/MS to identify and characterise in vitro and in vivo metabolites of danuglipron, providing a map of the biotransformation products formed from the parent molecule (PMID 40865303). Such work is descriptive: it identifies chemical species rather than establishing their clinical relevance (PMID 40865303).

Dosing frequency in trials

Clinical trials administered danuglipron orally on twice-daily schedules, and one phase 2 study compared distinct escalation schemes built around that frequency (PMID 37311722). The phase 1 multiple-ascending-dose design characterised exposure and pharmacodynamics over repeated administration in adults with type 2 diabetes (PMID 34127852).

Limits of the evidence in Module 5

Published pharmacokinetic information is fragmentary compared with an approved medicine: the verified record covers a renal-impairment study, metabolite identification and exposure characterisation within early trials, and does not include hepatic-impairment data, comprehensive drug–drug interaction studies, or population pharmacokinetic models. Metabolite identification does not establish metabolite activity or safety (PMID 40865303).

Module 6: Regulatory Status, Stated Factually

Approval status

Danuglipron is an investigational compound. It has no marketing authorisation as a medicine in the United States, the European Union or other major jurisdictions, and the peer-reviewed literature summarised here consists of phase 1 and phase 2 studies plus preclinical and analytical work (PMID 34127852, PMID 40539310). There is no approved danuglipron product, no approved labelling, and therefore no authorised indication, dose or population.

Research-use-only material

Chemical suppliers may list investigational small molecules as research-use-only (RUO) reference material. RUO designation means a substance is offered for laboratory work and is not a medicine: it carries no assurance of pharmaceutical-grade identity, purity or sterility, and it is not authorised for administration to humans or animals outside an approved research protocol.

Compounding

In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires that a bulk drug substance be the subject of an applicable USP or NF monograph, be a component of an FDA-approved drug, or appear on an FDA bulk drug substances list. An unapproved investigational small molecule that meets none of those conditions does not qualify as a compoundable bulk drug substance. This paragraph describes regulatory categories only and is not legal advice.

Distinguishing danuglipron from marketed GLP-1 medicines

Several peptide-based GLP-1 receptor agonists are approved medicines, and one oral peptide formulation is marketed; danuglipron is chemically distinct from these, being a non-peptide small molecule of the chemotype reviewed in the 2020–2024 patent literature (PMID 40873282). Findings reported for approved agents cannot be transferred to danuglipron, and vice versa.

Limits of the evidence in Module 6

Regulatory status is time-dependent and jurisdiction-specific. Programme decisions by sponsors, trial registrations and agency actions can change after any publication date, and the verified papers cited here describe study results rather than regulatory determinations.

What the Studies Did Not Test

The published record on danuglipron leaves large gaps, and it is worth stating them plainly:

• Long-term clinical outcomes. No verified study reported cardiovascular, renal or mortality outcomes; endpoints were HbA1c, body weight and safety over short trial durations (PMID 37213102, PMID 40539310).
• Human cardiac effects. The cardiac remodelling finding came from an animal pressure-overload model and was not tested in people (PMID 40070049).
• Off-target pharmacology in humans. The endocannabinoid-system crossover was a computational prediction without confirmatory clinical or laboratory verification in the verified literature (PMID 40838124).
• Special populations. Beyond the renal-impairment pharmacokinetic study (PMID 37840155), the verified record does not cover hepatic impairment, pregnancy, lactation, adolescents or older adults as distinct study populations.
• Head-to-head comparisons. Pooled analyses examined danuglipron alongside orforglipron against placebo comparators rather than in direct comparison with approved GLP-1 receptor agonists (PMID 37852529, PMID 41450584).
• Non-prescription or unsupervised use. No study evaluated danuglipron outside a monitored clinical trial setting, and no published evidence addresses material obtained outside that setting.

Readers using this course as a map of the literature should treat every statement above as a description of what specific studies reported in specific populations. This page is educational only and is not medical advice; questions about diabetes, obesity, or any medicine belong with a licensed physician.

References

• Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial (Nature Medicine, 2021)
• Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes: A Randomized Clinical Trial (JAMA Network Open, 2023)
• Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes (Diabetes, Obesity & Metabolism, 2023)
• Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials (Metabolism, 2023)
• Evaluating Glycemic Control Efficacy and Safety of the Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron in Type 2 Diabetes Patients: A Systemic Review and Meta-Analysis (Diabetes, Metabolic Syndrome and Obesity, 2023)
• Effect of Renal Impairment on the Pharmacokinetics of a Single Oral Dose of Danuglipron in Participants With Type 2 Diabetes (Journal of Clinical Pharmacology, 2024)
• Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study (Diabetes, Obesity & Metabolism, 2025)
• The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis (Frontiers in Endocrinology, 2025)
• Molecular docking of danuglipron uncovers potential crossovers between GLP-1R and the endocannabinoid system (microPublication Biology, 2025)
• Danuglipron Ameliorates Pressure Overload-Induced Cardiac Remodelling Through the AMPK Pathway (Journal of Cellular and Molecular Medicine, 2025)
• "Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024) (Current Medicinal Chemistry, 2025)
• Comprehensive identification and characterization of in vitro and in vivo metabolites of the novel GLP-1 receptor agonist danuglipron using UHPLC-QToF-MS/MS (Journal of Pharmaceutical and Biomedical Analysis, 2026)